| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.061 | 0.06 |
| mRNA | CD-1530 | CTRPv2 | pan-cancer | AAC | -0.07 | 0.06 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.055 | 0.07 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | -0.064 | 0.07 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | 0.094 | 0.07 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | -0.057 | 0.07 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.098 | 0.07 |
| mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | -0.076 | 0.08 |
| mRNA | Erlotinib | UHNBreast | pan-cancer | AAC | -0.48 | 0.08 |
| mRNA | N9-isopropylolomoucine | CTRPv2 | pan-cancer | AAC | -0.062 | 0.08 |